Bristol-Myers Squibb Company [BMY] stock Downgrade by Morgan Stanley analyst, price target now $62

Bristol-Myers Squibb Company [NYSE: BMY] price surged by 0.40 percent to reach at $0.26. The company report on May 6, 2021 that DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

DarwinHealth, a New York City-based biotechnology company, announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.

The methodology underpinning the NCTI is based on an understanding of critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations. To facilitate the discovery of NCTs, DarwinHealth will provide Bristol Myers Squibb proprietary information residing in its drug databases, including tumor context-specific analyses of Master Regulators of distinct tumor subtypes, as well as direct upstream modulators.

A sum of 10304073 shares traded at recent session while its average daily volume was at 12.12M shares. Bristol-Myers Squibb Company shares reached a high of $65.29 and dropped to a low of $64.59 until finishing in the latest session at $64.70.

The one-year BMY stock forecast points to a potential upside of 14.24. The average equity rating for BMY stock is currently 1.90, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $75.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 30, 2021. The new note on the price target was released on April 13, 2021, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another raise to $76, while Societe Generale analysts kept a Buy rating on BMY stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.02, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.38. The Price to Book ratio for the last quarter was 3.85, with the Price to Cash per share for the same quarter was set at 5.79. Price to Free Cash Flow for BMY in the course of the last twelve months was 15.92 with Quick ratio for the last quarter at 1.50.

BMY Stock Performance Analysis:

Bristol-Myers Squibb Company [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.92. With this latest performance, BMY shares gained by 3.34% in over the last four-week period, additionally plugging by 1.49% over the last 6 months – not to mention a rise of 5.98% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 54.18, with the RSI for the last a single of trading hit 53.71, and the three-weeks RSI is set at 54.49 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 63.13, while it was recorded at 64.45 for the last single week of trading, and 61.84 for the last 200 days.

Insight into Bristol-Myers Squibb Company Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +10.56 and a Gross Margin at +51.04. Bristol-Myers Squibb Company’s Net Margin is presently recorded at -21.20.

Return on Total Capital for BMY is now 4.76, given the latest momentum, and Return on Invested Capital for the company is -9.87. Return on Equity for this stock declined to -20.16, with Return on Assets sitting at -7.26. When it comes to the capital structure of this company, Bristol-Myers Squibb Company [BMY] has a Total Debt to Total Equity ratio set at 136.62. Additionally, BMY Total Debt to Total Capital is recorded at 57.74, with Total Debt to Total Assets ending up at 43.61. Long-Term Debt to Equity for the company is recorded at 130.00, with the Long-Term Debt to Total Capital now at 54.94.

Reflecting on the efficiency of the workforce at the company, Bristol-Myers Squibb Company [BMY] managed to generate an average of -$298,017 per employee. Receivables Turnover for the company is 4.54 with a Total Asset Turnover recorded at a value of 0.34.Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.60.


With the latest financial reports released by the company, Bristol-Myers Squibb Company posted 1.63/share EPS, while the average EPS was predicted by analysts to be reported at 1.48/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 7.80%.

Bristol-Myers Squibb Company [BMY] Insider Position Details

There are presently around $107,690 million, or 76.80% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 199,340,458, which is approximately -0.362% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 176,410,048 shares of the stock with an approximate value of $11.37 billion in BMY stocks shares; and STATE STREET CORP, currently with $6.07 billion in BMY stock with ownership of nearly -3.413% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,220 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 92,050,115 shares. Additionally, 982 investors decreased positions by around 92,391,986 shares, while 266 investors held positions by with 1,486,719,475 shares. The mentioned changes placed institutional holdings at 1,671,161,576 shares, according to the latest SEC report filing. BMY stock had 206 new institutional investments in for a total of 15,565,338 shares, while 111 institutional investors sold positions of 5,643,717 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam